Diagnos Inc. has added Richard Baxter, a co-founder of New Health Capital Partners, to its board. Diagnos is a maker of artificial intelligence and advanced knowledge-extraction technology. Baxter was previously co-head of Drawbridge Special Opportunities Health Care Group at Fortress Investment Group.
DIAGNOS inc. (“DIAGNOS” or “the Corporation”) CA:ADK -6.56% , a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, is pleased to announce the appointment of Mr Richard B. Baxter to the Board of Directors.
A co-founder of New Health Capital Partners in New York City, Mr. Baxter was previously the co-head of Drawbridge Special Opportunities Health Care Group at Fortress Investment Group LLC. A cum laude graduate (A.B., History) of Princeton University, Mr. Baxter also holds an MBA from the Harvard Business School. Mr. Baxter has extensive experience in the healthcare and finance industries acquired through senior executive roles in marketing and business development with US-based pharmaceutical and biopharmaceutical companies. His prior employers include Viropharma, Pathogenesis Corporation, Smithkline Beecham as well as Goldman, Sachs & Co.
“We are proud to have Rich join our board of directors. His extensive experience in the industry will help to guide us in our strategic plans. Rich brings a wealth of contacts, knowledge and insight that can be valuable for our future. Now that we have been granted FDA approval for CARA (Computer Assisted Retinal Analysis) we are accelerating marketing plans in the US” noted Andre Larente, President, Diagnos.
Mr. Baxter, who lives in Devon, Pensylvania, joins the current slate of members: Andre Larente, Olivier Lerolle, Bruno Maruzzo and Philip Renaud.
About New Health Capital Partners
New Health Capital Partners is headquartered in New York, NY and is focused on providing flexible, alternative source of capital to life sciences companies. The firm invests across the entire spectrum of healthcare companies and throughout the capital structure on a worldwide basis, including senior secured loans, monetization of royalty cash flow streams and the acquisition of “legacy” pharmaceutical products. NHCP is able to provide capital to commercial-stage, specialty pharmaceutical, medical devices, diagnostics and technology tools companies.
On September 20, 2011, New Health Capital Partners Fund 1 received an initial capital commitment of $150,000,000 from ORIX USA Asset Management, a global asset management firm.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation CA:ADK -6.56% , with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.
For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.